John Clarke

Dr. John Clarke

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Cancer Letters
Verified
Journal Article
Closed access
JCJohn Clarke
John Clarke
RDRoderick H. Dashwood
Roderick H. Dashwood
EHEmily Ho
Emily Ho

1 December 2009 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
EHEmily Ho
Emily Ho
JCJohn Clarke
John Clarke
RDRoderick H. Dashwood
Roderick H. Dashwood
The reversible acetylation of histones is an important mechanism of gene regulation. During prostate cancer progression, specific modifications in ac

1 November 2011 in Pharmacological Research
Verified
Journal Article
Closed access
JCJohn Clarke
John Clarke
AHAnna Hsu
Anna Hsu
KRKen Riedl
Ken Riedl
DBDeborah Bella
Deborah Bella
SSSteven Schwartz
Steven Schwartz
EHEmily Ho
Emily Ho

17 June 2011 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
JCJohn Clarke
John Clarke
AHAnna Hsu
Anna Hsu
DWDavid E. Williams
David E. Williams
RDRoderick H. Dashwood
Roderick H. Dashwood
JSJan Frederik Stevens
Jan Frederik Stevens
EHEmily Ho
Emily Ho

4 March 2011 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
JCJohn Clarke
John Clarke
AHAnna Hsu
Anna Hsu
ZYZhen Yu
Zhen Yu
RDRoderick H. Dashwood
Roderick H. Dashwood
EHEmily Ho
Emily Ho

29 July 2021 in Toxins
Verified
Journal Article
Open access
PDF file
TATarana Arman
Tarana Arman
JCJohn Clarke
John Clarke
Microcystins are ubiquitous toxins produced by photoautotrophic cyanobacteria. Human exposures to microcystins occur through the consumption of contaminated drinking water, fish and shellfish, vegetables, and algal dietary supplements and through recreational activities. Microcystin-leucine-arginine (MCLR) is the prototypical microcystin because it is reported to be the most common and toxic variant and is the only microcystin with an established tolerable daily intake of 0.04 µg/kg. Microcystin toxicokinetics is characterized by low intestinal absorption, rapid and specific distribution to the liver, moderate metabolism to glutathione and cysteinyl conjugates, and low urinary and fecal excretion. Molecular toxicology involves covalent binding to and inhibition of protein phosphatases, oxidative stress, cell death (autophagy, apoptosis, necrosis), and cytoskeleton disruption. These molecular and cellular effects are interconnected and are commonly observed together. The main target organs for microcystin toxicity are the intestine, liver, and kidney. Preclinical data indicate microcystins may also have nervous, pulmonary, cardiac, and reproductive system toxicities. Recent evidence suggests that exposure to other hepatotoxic insults could potentiate microcystin toxicity and increase the risk for chronic diseases. This review summarizes the current knowledge for microcystin toxicokinetics, molecular toxicology, and pathophysiology in preclinical rodent models and humans. More research is needed to better understand human toxicokinetics and how multifactorial exposures contribute to disease pathogenesis and progression.